Other GLP-1 Receptor Agonists: A Comprehensive Comparison does not replace medical advice, diagnosis, or treatment
Options include staying at your current dose longer before increasing, temporarily reducing to your previous dose level, implementing more aggressive side effect management strategies, or in some cases discontinuing treatment
MC4R, melanocortin 4 receptor-expressing
These values reflect research protocols only and are presented for research-use-only reference, never as medical guidance
PCOS and GLP-1s: Improving Reproductive Functionality For PCOS, the human evidence on GLP-1 medications is compelling enough that they now feature in the 2023 International PCOS Guidelines, though as a conditional recommendation (1)
Introduction# Semaglutide and survodutide represent two generations of incretin-based obesity therapeutics